Overview

Doravirine and Weight Gain in Antiretroviral Naive

Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is determine whether different antiretroviral therapy (ART) changes the effects on body fat and predict the weight change in Black and Hispanic females.
Phase:
Phase 3
Details
Lead Sponsor:
Prism Health North Texas
Collaborator:
Merck Sharp & Dohme LLC
Treatments:
Emtricitabine tenofovir alafenamide